Who is sponsoring NCT02228681?

NCT02228681 is sponsored by GOG Foundation.

What condition does NCT02228681 study?

NCT02228681 studies Advanced, Persistent, or Recurrent Endometrial Cancer.

What drugs are being tested in NCT02228681?

Interventions: Everolimus, Tamoxifen, Letrozole, Medroxyprogesterone Acetate.

What is the status of NCT02228681?

NCT02228681 is currently COMPLETED.

Last reviewed 2024-08-30 · How we verify

A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma

NCT02228681 Phase 2 COMPLETED Results posted

The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.

Details

Lead sponsor	GOG Foundation
Phase	Phase 2
Status	COMPLETED
Enrolment	74
Start date	2015-05-21
Completion	2024-08-22

Conditions

Advanced, Persistent, or Recurrent Endometrial Cancer

Interventions

Everolimus
Tamoxifen
Letrozole
Medroxyprogesterone Acetate

Primary outcomes

Frequency of Response — From date of randomization until the date of first documented progression or date of death , up to 3 years.
A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Countries

United States